MedTrace Logo

The Effectiveness of the "MINDLiNG" Digital Mental Health Intervention

NCT06166693 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2023-12-15

No results posted yet for this study

Summary

A study in South Korea assessed the effectiveness of the "MINDLiNG" digital mental healthcare program, targeting maladaptive personality traits, and found significant improvements in reducing stress, perfectionism, loneliness, and anxiety, while increasing self-esteem among participants. The study highlights the potential of digital solutions to address the high demand for mental healthcare services in South Korea.

Conditions

  • Mental Health Services
  • Personality

Interventions

DEVICE

"MINDLiNG" Digital Mental Health Intervention

The intervention was delivered on an online platform set up separately for the study, which was accessible via the web browser and application. The psychological intervention program for maladaptive personality traits (Mindling) is based on the principles of CBT, psychological schema therapy, acceptance-commitment therapy, and mindfulness-based cognitive therapy, and is aimed primarily at adults to prevent and overcome psychological difficulties

Sponsors & Collaborators

  • The Ministry of SMEs and Startups. South Korea

    collaborator UNKNOWN

  • 40FY

    lead INDUSTRY

Principal Investigators

  • Min-Sup Shin, PhD · Seoul National University College of Medicine, Department of Psychiatry

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-23
Primary Completion
2023-05-31
Completion
2023-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06166693 on ClinicalTrials.gov